查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1855587

乳糜瀉治療市場：2025-2032年全球預測（依治療類型、藥物類別、給藥通路、通路、劑型、最終使用者、年齡層及適應症分期分類）

Celiac Disease Drugs Market by Therapy Type, Drug Class, Route Of Administration, Distribution Channel, Dosage Form, End User, Age Group, Indication Stage - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 199 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，乳糜瀉治療市場規模將達到 35.9 億美元，複合年成長率為 10.95%。

關鍵市場統計數據
基準年 2024 15.6億美元
預計年份：2025年 17.3億美元
預測年份 2032 35.9億美元
複合年成長率 (%) 10.95%

為影響乳糜瀉藥物研發的不斷變化的治療和商業環境提供了引人入勝的背景訊息

乳糜瀉的治療模式已從以飲食管理為主轉變為以分子生物學、免疫學和製劑科學的進步為驅動的蓬勃發展的治療領域。這種轉變推動了臨床治療的深入，從透過避免麩質來控制症狀，轉向改善潛在的疾病機制、促進黏膜癒合和減少長期併發症。這促使業界、臨床實踐和相關人員在評估各種機會的同時，權衡臨床相關性與供應和報銷的實際情況。

同時，患者的期望也在不斷變化。公眾意識的提高、診斷演算法的改進以及患者權益倡導的加強，都推動了對能夠減輕日常生活負擔並切實改善生活品質的治療方法的需求。同時，監管機構和支付方也不斷完善評估療效和長期價值的架構。所有這些因素共同構成了一個複雜且動態的環境，在這個環境中，治療方法創新必須在臨床上可靠、商業性可行且運作上可行，才能被廣泛採用。

對重塑乳糜瀉治療藥物臨床開發、給藥模式和商業化路徑的變革性轉變進行策略性概述

治療領域正經歷多重整合的轉變，這些轉變正在重新調整研發者和醫療保健系統的優先事項。首先，作用機制多樣化正在加速。旨在分解攝取麩質的酵素療法、旨在抑制抗原特異性免疫反應的靶向免疫調節劑以及作用於腸道菌群的益生菌，各自遵循不同的生物學原理。這種多方面的方法增加了差異化產品的可能性，同時也使不同療法之間的比較評估變得更加複雜。

其次，治療方式和分子創新正在改變臨床試驗設計和監管參與方式。生物製藥和工程化小分子藥物在生產、穩定性和遞送方面需要考慮不同的因素，這會影響研發週期和資金投入。將口服藥物與生物目標佐劑結合的混合開發策略正在興起，旨在平衡療效和患者便利性。第三，分銷和醫療服務模式正在不斷演變。線上處方服務的擴展和居家照護管理途徑的日益成熟正在改變治療藥物到達患者手中的方式以及依從性監測的方式，從而影響商業模式和與支付方的關係。

生物技術創新者、合約研究製造商、專業藥房和臨床網路之間的策略夥伴關係變得至關重要，因為它們可以加快獲取專業知識的速度，降低營運風險，並實現更靈活的商業化策略，涵蓋不同的給藥途徑和最終用戶環境。

對2025年美國關稅政策變化對乳糜瀉藥物研發、生產和供應鏈的累積影響進行定性分析

近期關稅政策的變化加劇了全球藥品供應鏈的複雜性，並對乳糜瀉藥物的研發、生產和分銷產生了連鎖反應。原料藥和特殊輔料關稅的提高推高了新型生物製藥和小分子藥物的上游投入成本。為此，製藥公司正在重新評估其供應商組合，加快對替代供應商的資格認證，並評估將關鍵生產流程外包或遷回國內的可能性，以降低貿易波動帶來的風險。

這些變化也會影響臨床藥物採購和生產規模擴大的策略決策。在多個國家進行臨床試驗的公司面臨運輸臨床實驗藥物和樣本的物流成本不斷上漲的問題。此外，關稅也可能影響最終的劑型和給藥途徑。與穩定的口服製劑相比，依賴特殊注射給藥系統或低溫運輸運輸的生技藥品治療方法會受到更大的影響。

鑑於成本壓力，支付方和採購機構也在調整合約預期，這促使製造商加強其價值主張並探索風險分擔機制。整體提案，關稅情勢促使各方採取多管齊下的應對措施，包括供應鏈多元化、關鍵流程的策略性本地化、優先發展成本效益高的劑型，以及加強與下游分銷夥伴的談判，以確保藥品的可及性和可負擔性。

透過考慮治療方法、藥物類別、給藥途徑、分銷管道、劑型、最終用戶、年齡和適應症階段等因素，提供可操作的細分洞察，從而指導策略重點。

市場細分錶明，不同類型的治療方法——酶製劑、免疫調節劑和益生菌——具有不同的臨床價值提案和操作要求。酵素製劑優先考慮口服製劑的穩定性以及在飲食方案中可預測的活性；免疫調節劑需要先進的安全性監測和腸外給藥的可能性；益生菌則強調菌株選擇、保存期限管理和監管分類等方面的細微差別。這些差異會影響研發週期、監管策略以及獲得醫保認可所需的證據材料。

將藥物分為生物製藥和小分子藥物兩大類，會進一步影響生產的複雜性和供應鏈風險。生物製藥通常需要專門的生產設施、低溫運輸物流和更高的資本投入，而小分子藥物的生產流程可能更成熟，口服給藥方式也更有彈性。將給藥途徑分為注射劑和口服劑，會影響患者的順從性、即時照護、醫療保險報銷模式。口服製劑可由患者自行給藥，門診病人更容易取得，而注射劑可能需要診所或家庭護理護理師的參與。

將分銷管道細分為醫院藥房、線上藥房和零售藥房，可以揭示具有商業性價值的獲取途徑。醫院藥局（包括公立和私立醫院）對於在急診和專科診所分發生技藥品仍然至關重要，而線上藥局（包括非處方藥和處方箋服務）則能夠涵蓋更廣泛的地域，並提供更大的便利性。零售藥局（包括連鎖藥局和獨立藥局）則支持慢性病維持治療和第一線病患互動。劑型細分，例如注射劑、口服膠囊、口服錠劑和粉末，直接影響藥物的穩定性、依從性和生產過程的權衡，進而影響定價和保存期限策略。

將終端使用者細分為居家照護、醫院和專科診所，有助於明確治療路徑。居家照護支持長期維持治療，無論是由護理師協助或是病人自行用藥，都能減輕醫院的負擔。同時，醫院和專科診所仍然是急性期治療和複雜免疫調節方案的核心場所。區分成人和兒童年齡層需要製定相應的安全性、劑量和製劑方案，而兒童藥物的研發通常需要專門的研究和製劑。最後，將適應症分為急性期治療和維持治療，可以建立監管部門核准和醫保報銷所需的證據等級，其中急性期干預措施的評估主要依據快速臨床終點，而維持治療則通常根據療效的持久性和長期結果來評判。

關鍵區域洞察：比較美洲、歐洲、中東和非洲以及亞太地區的促進因素、採用動態和政策環境

在美洲，強大的診斷基礎設施、眾多的胃腸病學專家以及充滿活力的風險投資和生物技術生態系統，促進了差異化治療方法的快速臨床開發和早期商業化。該地區的支付方框架通常強調療效比較和長期結果，傾向於選擇具有明確療效的治療方法。打入市場策略通常需要直接比較證據和真實世界結果數據，以支持高定價和納入處方箋目錄。

歐洲、中東和非洲的情況與實行單一支付方或多支付方醫療體系且專科醫生資源有限的地區形成鮮明對比。歐洲監管機構強調全面的安全數據，並經常將衛生技術評估納入報銷決策。某些市場的集中採購和激烈的價格談判要求製造商建立完善的衛生經濟模型，並儘早與當地衛生部門接洽，以使臨床開發和報銷預期保持一致。

亞太地區由於診斷技術的擴展、專科醫療能力的提升以及公共和私人對生物技術投資的增加，展現出快速推廣應用的潛力。然而，各地法規環境差異巨大，通常要求製造商制定獨特的研發和商業化藍圖，以適應當地的註冊要求、不同的報銷機制和多樣化的分銷系統。在任何地區，與當地臨床網路合作、投資於真實世界證據的生成以及製定靈活的定價和准入方案，都將提高成功推廣應用的可能性。

公司層面的策略洞察，重點在於影響產品線優先排序、生產製造和市場進入決策的競爭與合作行為。

在乳糜瀉治療領域，主要企業正採取差異化策略，將自主研發與策略夥伴關係結合。生物技術公司通常專注於早期機制檢驗和市場定位，並利用目標臨床終點來概念驗證。大型製藥公司通常透過先進的生產製造、監管專業知識和成熟的商業網路來擴大規模，並在建立夥伴關係和許可協議後，加速後期研發，以實現更廣泛的市場推廣。

整個製藥產業都在投資提升自身能力，以降低生產風險並縮短產品上市時間。這些投資包括生技藥品和小分子藥物的契約製造關係、口服和粉劑製劑的專業配方技術，以及用於依從性和療效追蹤的數位化健康整合。競爭格局也正在推動互補資產的整合，包括資產收購、共同開發契約和合作商業化協議。此類合作方式有助於分散風險、集中資源進行昂貴的後期臨床試驗，並協調用於跨國申報的臨床資料包。

最後，那些能夠將臨床差異化與現實的商業化計劃相結合，從而持續取得成功的公司，將證據生成與支付方的期望相一致，建立可擴展的生產網路，並設計以患者為中心的交付模式，使其適用於住院、專科診所和居家醫療管道。

為產業領導者提供行動建議，以加速乳糜瀉藥物的研發、最佳化藥物可及性並建立穩健的商業化模式。

首先，透過將重要結局指標納入臨床試驗設計和規劃，使臨床開發與支付方和患者的優先事項保持一致，以便儘早獲得真實世界證據。這種方法可以縮小監管核准與支付方接受度之間的差距，並強化支持有利報銷的價值主張。其次，透過對關鍵投入品的多個供應商進行資格認證、探索區域生產方案以及在臨床可行的情況下設計盡可能減少低溫運輸依賴的劑型，實現供應鏈多元化並降低風險。這些措施可以降低關稅和物流的風險，並提高對需求變化的應對力。

第三，採取適應性商業化策略，確保複雜的免疫調節方案能夠獲得醫院和專科診所的認可，同時利用線上處方服務和零售網路進行維持治療。將產品上市計劃與患者支持項目結合，可以提高患者依從性和改善實際療效。第四，優先發展策略夥伴關係。與委外研發機構、專科藥局和臨床網路合作，可以充分利用技術優勢，加速產品進入市場。最後，投資以患者為中心的製劑研發和兒科適用劑量方案，將擴大目標族群，並降低不同醫療機構採用該藥物的障礙。

對用於獲得有關乳糜瀉藥物的可靠、可操作見解的調查方法進行透明概述

本研究整合了第一手資料和第二手資料，以全面了解治療、商業和監管方面的動態。第一手資料包括與相關人員進行結構化訪談和討論，這些利害關係人包括臨床醫生、支付方代表、供應鏈專家、業務拓展負責人和病患權益倡導團體，旨在了解他們對未滿足需求、推廣障礙和證據要求的真實觀點。第二手資料則包括對同儕審查文獻、臨床試驗註冊庫、監管指南和公開的企業資料進行系統性回顧，以揭示發展趨勢和監管機構的期望。

為了確保分析結果的穩健性，本研究採用了定性綜合和跨資料來源交叉檢驗的方法。研究運用細分框架，從治療方法類型、藥物類別、給藥途徑、分銷管道、劑型、最終用戶、年齡層和適應症階段等維度對研究結果進行解讀。區域分析考慮了監管、支付方和醫療服務體系方面的差異。調查方法強調證據三角驗證、基於情境的政策影響評估，以及將技術發現轉化為相關人員可執行的策略建議。

簡潔的結論整合了對相關人員在不斷變化的乳糜瀉治療領域中尋求發展和引領的策略意義。

兒童乳糜瀉治療領域正日益成熟，成為一個多方面的生態系統，機制創新與複雜的商業性、通路以及支付方的證據要求，才能將臨床前景轉化為病患可近性。供應鏈和政策的發展，包括關稅相關的變化，進一步凸顯了設計具有韌性的研發和商業化策略的必要性。

成功將青睞那些將嚴謹的臨床差異化與靈活的營運模式相結合、儘早與支付方和臨床醫生溝通以協調證據生成和價值預期、並建立與自身能力互補的夥伴關係關係的機構。透過推行以患者為中心的製劑策略、實現供應鏈多元化以及根據當地實際情況調整商業化策略，相關人員可以提高新型乳糜瀉療法在臨床應用和永續可及性方面取得成效的幾率。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

  • 增加對口服酵素療法的投資，以期在胃腸道中分解麩質
  • 旨在恢復腸道屏障功能的個人化益生菌配方研究進展
  • 開發旨在持續誘導患者麩質耐受性的免疫調節生技藥品
  • 生技企業與學術中心之間合作的加強加速了緊密連接調變器的研究
  • 數位化依從性監測平台的應用日益普及，以提高無麩質飲食的依從性
  • First-in-Class可預防自體免疫反應的轉谷氨醯胺酶2抑制劑正獲得監管部門的密切關注。
  • 重點研究表位特異性肽療法，以降低麩質誘導的免疫反應的敏感性

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

8. 依治療類型分類的乳糜瀉治療市場

  • 酵素療法
  • 免疫調節療法
  • 益生菌療法

9. 依藥物類別分類的乳糜瀉治療市場

  • 生物製藥
  • 低分子

10. 依給藥途徑分類的乳糜瀉治療市場

  • 注射
  • 口服

第11章 依通路分類的乳糜瀉治療市場

  • 醫院藥房
    • 私立醫院
    • 公立醫院
  • 網路藥房
    • 場外交易服務
    • 處方箋服務
  • 零售藥房
    • 連鎖藥局
    • 獨立藥房

第12章 依劑型分類的乳糜瀉治療市場

  • 注射
  • 口服膠囊
  • 口服錠劑
  • 粉末劑型

第13章 依最終使用者分類的乳糜瀉治療市場

  • 居家照護
    • 護士助理管理
    • 自我管理
  • 醫院
    • 私立醫院
    • 公立醫院
  • 專科診所
    • 消化診所
    • 一般診所

14. 依年齡層分類的乳糜瀉治療市場

  • 成人
  • 孩子們

第15章：依適應症階段分類的乳糜瀉治療市場

  • 急性治療
  • 維持治療

16. 各地區乳糜瀉治療市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第17章 按群體分類的乳糜瀉治療市場

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

18. 各國乳糜瀉治療市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第19章 競爭情勢

  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 競爭分析
    • Takeda Pharmaceutical Company Limited
    • Amgen Inc.
    • Provention Bio, Inc.
    • Alvine Therapeutics, Inc.
    • Zedira GmbH
    • Nexpep Pty Ltd
    • Royal DSM NV
    • Innovate Biopharmaceuticals, Inc.
Product Code: MRR-4659C87123C2

The Celiac Disease Drugs Market is projected to grow by USD 3.59 billion at a CAGR of 10.95% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 1.56 billion
Estimated Year [2025] USD 1.73 billion
Forecast Year [2032] USD 3.59 billion
CAGR (%) 10.95%

Compelling contextual introduction to the evolving therapeutic and commercial environment shaping celiac disease drug development

Celiac disease has transitioned from a predominantly dietary management paradigm to a vibrant therapeutic landscape driven by advances in molecular biology, immunology, and formulation science. This shift has elevated the clinical ambition from symptom control through gluten avoidance to modifying underlying disease mechanisms, improving mucosal healing, and reducing long-term complications. As a result, stakeholders across industry, clinical practice, and payers now evaluate opportunities through a lens that balances clinical meaningfulness with practical delivery and reimbursement realities.

Concurrently, patient expectations are evolving. Increased awareness, improved diagnostic algorithms, and organized patient advocacy have amplified demand for therapies that reduce daily burden and provide measurable improvements in quality of life. Healthcare delivery is adapting to accommodate novel modalities and administration settings, while regulators and payers refine frameworks to assess comparative benefit and long-term value. Taken together, these factors create a complex, dynamic environment where therapeutic innovation must be clinically robust, commercially viable, and operationally executable to achieve adoption.

Strategic overview of the transformative shifts reordering clinical development, delivery models, and commercialization pathways in celiac disease therapeutics

The therapeutic landscape is experiencing multiple convergent shifts that are reshaping priorities for developers and healthcare systems. First, mechanistic diversification has accelerated: enzyme therapies aimed at degrading ingested gluten, targeted immunomodulators designed to blunt antigen-specific immune responses, and microbiome-directed probiotics each pursue distinct biological rationales. This pluralistic approach increases the probability of differentiated products while complicating comparative assessments across modalities.

Second, modality and molecule innovations have altered clinical trial design and regulatory engagement. Biologic agents and engineered small molecules require distinct manufacturing, stability, and delivery considerations, which affects timelines and capital intensity. Hybrid development strategies that pair oral formulations with targeted biologic adjuncts are emerging to reconcile efficacy with patient convenience. Third, distribution and care delivery models are evolving. Expansion of online prescription services and the maturation of homecare administration pathways are changing how therapies reach patients and how adherence is monitored, thereby influencing commercial models and payer interactions.

Finally, collaborative ecosystems are maturing; strategic partnerships between biotech innovators, contract development manufacturers, specialty pharmacies, and clinical networks are becoming essential. These alliances accelerate access to specialized capabilities, mitigate operational risk, and enable more flexible commercialization strategies that align with diverse routes of administration and end-user settings.

Qualitative analysis of the cumulative impacts of United States tariff policy shifts in 2025 on celiac disease drug development, manufacturing, and supply chains

Recent tariff policy changes have introduced added complexity to global pharmaceutical supply chains, with implications that ripple through development, manufacturing, and distribution of celiac disease therapies. Increased tariffs on active pharmaceutical ingredients and specialized excipients have raised upstream input costs for both novel biologics and small molecule formulations. In response, sponsors are reassessing supplier portfolios, accelerating qualification of alternative vendors, and evaluating nearshoring or repatriation of critical manufacturing steps to reduce exposure to trade-driven volatility.

These shifts also influence strategic decisions around clinical sourcing and manufacturing scale-up. Companies conducting multinational clinical trials face higher logistics costs for investigational product movement and sample transport, which can increase protocol complexity and necessitate greater contingency planning. Moreover, tariffs can affect choices of final dosage form and route of administration; therapies that rely on specialized injectable delivery systems or cold-chain dependent biologics may be disproportionately impacted compared with stable oral formulations.

Payers and procurement entities are also adjusting contracting expectations in light of cost pressures, prompting manufacturers to strengthen value propositions and explore risk-sharing arrangements. Overall, the tariff landscape encourages a multi-pronged response that includes supply chain diversification, strategic localization of critical processes, prioritization of cost-efficient dosage forms, and intensified negotiation with downstream distribution partners to preserve access and affordability.

Actionable segmentation insights that translate therapy, drug class, route, distribution, dosage form, end-user, age, and indication stage considerations into strategic priorities

Segmentation reveals that therapy type distinctions-enzyme therapy, immunomodulator therapy, and probiotic therapy-create discrete clinical value propositions and operational requirements. Enzyme therapies prioritize robust oral formulation stability and predictable activity across dietary contexts, immunomodulators demand sophisticated safety monitoring and potentially parenteral administration pathways, while probiotics emphasize strain selection, shelf-life management, and regulatory classification nuances. These differences influence development timelines, regulatory strategy, and the evidence package required for payer acceptance.

Drug class segmentation into biological and small molecule categories further determines manufacturing complexity and supply chain risk. Biologicals typically require specialized facilities, cold-chain logistics, and higher capital intensity, whereas small molecules offer more established manufacturing routes and potentially broader oral dosing flexibility. Route of administration segmentation between injectable and oral options affects patient adherence, site-of-care considerations, and reimbursement models; oral therapies favor self-administration and broader outpatient access, while injectables may necessitate clinic- or home-based nurse involvement.

Distribution channel segmentation across hospital pharmacies, online pharmacies, and retail pharmacies highlights commercially relevant access routes. Hospital pharmacies, encompassing private and public hospitals, remain critical for acute and specialty clinic-dispensed biologics, while online pharmacies, including OTC and prescription services, enable broader geographic reach and convenience. Retail pharmacies, both chain and independent, support chronic maintenance therapies and front-line patient engagement. Dosage form segmentation-injectable formulation, oral capsules, oral tablets, and powder form-maps directly to stability, adherence, and manufacturing trade-offs that influence pricing and shelf-life strategies.

End-user segmentation into homecare settings, hospitals, and specialty clinics clarifies care pathways. Homecare, whether nurse assisted administration or self-administration, supports long-term maintenance therapies and reduces hospital burden, whereas hospital and specialty clinic settings remain central for acute management and complex immunomodulatory regimens. Age group segmentation, distinguishing adults and pediatrics, requires tailored safety, dosing, and formulation approaches, with pediatric development often demanding dedicated trials and formulations. Finally, indication stage segmentation between acute management and maintenance therapy shapes the evidence hierarchy needed for regulatory approval and payer reimbursement, with acute interventions often evaluated on rapid clinical endpoints and maintenance therapies judged on durability and long-term outcomes.

Key regional insights that compare drivers, adoption dynamics, and policy environments across the Americas, Europe Middle East & Africa, and Asia-Pacific regions

In the Americas, strong diagnostic infrastructure, concentrated centers of gastroenterology expertise, and an active venture and biotech ecosystem drive rapid clinical development and early commercialization of differentiated therapies. Payer frameworks in this region often emphasize comparative effectiveness and long-term outcomes, which favors therapies with clear demonstrable benefits. Market access strategies frequently require head-to-head evidence or real-world outcomes data to support premium pricing and formulary placement.

Europe, the Middle East & Africa presents a heterogeneous landscape where single-payer and multi-payer systems contrast with regions that have limited specialist access. Regulatory pathways in Europe value comprehensive safety data and often incorporate health technology assessment into reimbursement decisions. In several markets, centralized procurement and stringent price negotiation practices encourage manufacturers to develop strong health economic models and engage early with regional health authorities to align clinical development with reimbursement expectations.

Asia-Pacific exhibits rapid adoption potential driven by expanding diagnostics, growing specialty care capacity, and increasing public and private investment in biotechnology. However, regulatory environments vary widely, and manufacturers often need tailored development and commercialization roadmaps that account for local registration requirements, differential reimbursement mechanisms, and diverse distribution ecosystems. Across all regions, collaboration with local clinical networks, investment in real-world evidence generation, and adaptive pricing or access programs enhance the likelihood of successful adoption.

Strategic company-level insights highlighting the competitive and collaborative behaviors shaping pipeline prioritization, manufacturing, and market entry decisions

Leading organizations in the celiac disease therapeutic arena are pursuing differentiated strategies that combine internal development with strategic partnerships. Biotech innovators often concentrate on early-stage mechanistic validation and niche positioning, leveraging targeted clinical endpoints to demonstrate proof of concept. Larger pharmaceutical firms typically bring scale through advanced manufacturing, regulatory expertise, and established commercial networks, enabling accelerated late-stage development and broader market rollout when partnerships or licensing agreements align.

Across the sector, companies are investing in capabilities that de-risk production and improve time-to-market. This includes contract manufacturing relationships for biologics and small molecules, specialized formulation expertise for oral and powder forms, and digital health integrations for adherence and outcome tracking. Competitive dynamics are also driving consolidation of complementary assets, whether through asset acquisitions, co-development deals, or joint commercialization agreements. This collaborative approach helps distribute risk, pool resources for expensive late-stage trials, and harmonize clinical data packages for multinational submissions.

Finally, companies that succeed most consistently are those that integrate clinical differentiation with pragmatic commercialization planning-aligning evidence generation to payer expectations, building scalable manufacturing networks, and designing patient-centric delivery models that work across inpatient, specialty clinic, and homecare channels.

Actionable recommendations for industry leaders to accelerate development, optimize access, and build resilient commercialization models for celiac therapies

First, align clinical development with payer and patient priorities by embedding outcomes that matter into trial design and by planning real-world evidence generation early. This approach reduces the gap between regulatory approval and payer acceptance and enhances the value narrative that supports favorable reimbursement. Second, diversify and de-risk supply chains by qualifying multiple suppliers for critical inputs, exploring regional manufacturing options, and designing dosage forms that minimize cold-chain dependence when clinically feasible. These steps mitigate tariff and logistics vulnerabilities and improve responsiveness to demand shifts.

Third, pursue adaptive commercialization strategies that leverage online prescription services and retail networks for maintenance therapies while reserving hospital and specialty clinic pathways for complex immunomodulatory regimens. Coupling product launch plans with tailored patient support programs can enhance adherence and real-world outcomes. Fourth, prioritize strategic collaborations-partner with contract development organizations, specialty pharmacies, and clinical networks to access technical capabilities and accelerate market entry. Finally, invest in patient-centric formulation development and pediatric-friendly dosing options to broaden addressable populations and reduce barriers to adoption across care settings.

Transparent overview of the research methodology employed to generate robust, actionable insights into celiac disease therapeutics

This research synthesized primary and secondary inputs to develop a comprehensive understanding of therapeutic, commercial, and regulatory dynamics. Primary research consisted of structured interviews and discussions with stakeholders including clinicians, payer representatives, supply chain experts, business development leaders, and patient advocacy groups to capture real-world perspectives on unmet needs, adoption barriers, and evidence requirements. Secondary research included a systematic review of peer-reviewed literature, clinical trial registries, regulatory guidelines, and publicly available company disclosures to contextualize development trends and regulatory expectations.

Analytical methods integrated qualitative synthesis with cross-validation across data sources to ensure robustness. Segmentation frameworks were applied to interpret findings across therapy type, drug class, route of administration, distribution channel, dosage form, end-user, age group, and indication stage. Regional analyses considered regulatory, payer, and delivery system heterogeneity. The methodology emphasized triangulation of evidence, scenario-based assessment of policy impacts, and the translation of technical findings into actionable strategic recommendations for stakeholders.

Concise conclusion that synthesizes strategic implications for stakeholders seeking to navigate and lead in the evolving celiac disease therapeutic landscape

The celiac disease therapeutic landscape is maturing into a multifaceted ecosystem where mechanistic innovation intersects with complex commercial and operational realities. Developers must balance scientific ambition with pragmatic considerations-manufacturing requirements, route-of-administration trade-offs, distribution pathways, and payer evidence demands-to convert clinical promise into patient access. Supply chain and policy developments, including tariff-related shifts, add further imperatives to design resilient development and commercialization strategies.

Success will favor organizations that integrate rigorous clinical differentiation with flexible operational models, that engage early with payers and clinicians to align evidence generation with value expectations, and that build partnerships to complement internal capabilities. By pursuing patient-centric formulation strategies, diversifying supply chains, and tailoring commercialization to regional idiosyncrasies, stakeholders can improve the odds of achieving both clinical impact and sustainable access for new celiac disease therapies.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Increased investment in oral enzyme therapies targeting gluten breakdown in the digestive tract
  • 5.2. Advancement in personalized probiotic formulations designed to restore intestinal barrier function
  • 5.3. Development of immunomodulatory biologics aiming to induce sustained gluten tolerance in patients
  • 5.4. Rising collaboration between biotech companies and academic centers accelerating tight junction modulator research
  • 5.5. Growing adoption of digital adherence monitoring platforms to improve gluten-free diet compliance
  • 5.6. Regulatory momentum for first-in-class transglutaminase 2 inhibitors to prevent autoimmune response
  • 5.7. Focus on epitope-specific peptide therapies to desensitize immune reactions triggered by gluten

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Celiac Disease Drugs Market, by Therapy Type

  • 8.1. Enzyme Therapy
  • 8.2. Immunomodulator Therapy
  • 8.3. Probiotic Therapy

9. Celiac Disease Drugs Market, by Drug Class

  • 9.1. Biological
  • 9.2. Small Molecule

10. Celiac Disease Drugs Market, by Route Of Administration

  • 10.1. Injectable
  • 10.2. Oral

11. Celiac Disease Drugs Market, by Distribution Channel

  • 11.1. Hospital Pharmacies
    • 11.1.1. Private Hospital
    • 11.1.2. Public Hospital
  • 11.2. Online Pharmacies
    • 11.2.1. Otc Service
    • 11.2.2. Prescription Service
  • 11.3. Retail Pharmacies
    • 11.3.1. Chain Pharmacy
    • 11.3.2. Independent Pharmacy

12. Celiac Disease Drugs Market, by Dosage Form

  • 12.1. Injectable Formulation
  • 12.2. Oral Capsules
  • 12.3. Oral Tablets
  • 12.4. Powder Form

13. Celiac Disease Drugs Market, by End User

  • 13.1. Homecare Settings
    • 13.1.1. Nurse Assisted Administration
    • 13.1.2. Self Administration
  • 13.2. Hospitals
    • 13.2.1. Private Hospitals
    • 13.2.2. Public Hospitals
  • 13.3. Specialty Clinics
    • 13.3.1. Gastroenterology Clinics
    • 13.3.2. General Clinics

14. Celiac Disease Drugs Market, by Age Group

  • 14.1. Adults
  • 14.2. Pediatrics

15. Celiac Disease Drugs Market, by Indication Stage

  • 15.1. Acute Management
  • 15.2. Maintenance Therapy

16. Celiac Disease Drugs Market, by Region

  • 16.1. Americas
    • 16.1.1. North America
    • 16.1.2. Latin America
  • 16.2. Europe, Middle East & Africa
    • 16.2.1. Europe
    • 16.2.2. Middle East
    • 16.2.3. Africa
  • 16.3. Asia-Pacific

17. Celiac Disease Drugs Market, by Group

  • 17.1. ASEAN
  • 17.2. GCC
  • 17.3. European Union
  • 17.4. BRICS
  • 17.5. G7
  • 17.6. NATO

18. Celiac Disease Drugs Market, by Country

  • 18.1. United States
  • 18.2. Canada
  • 18.3. Mexico
  • 18.4. Brazil
  • 18.5. United Kingdom
  • 18.6. Germany
  • 18.7. France
  • 18.8. Russia
  • 18.9. Italy
  • 18.10. Spain
  • 18.11. China
  • 18.12. India
  • 18.13. Japan
  • 18.14. Australia
  • 18.15. South Korea

19. Competitive Landscape

  • 19.1. Market Share Analysis, 2024
  • 19.2. FPNV Positioning Matrix, 2024
  • 19.3. Competitive Analysis
    • 19.3.1. Takeda Pharmaceutical Company Limited
    • 19.3.2. Amgen Inc.
    • 19.3.3. Provention Bio, Inc.
    • 19.3.4. Alvine Therapeutics, Inc.
    • 19.3.5. Zedira GmbH
    • 19.3.6. Nexpep Pty Ltd
    • 19.3.7. Royal DSM N.V.
    • 19.3.8. Innovate Biopharmaceuticals, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY THERAPY TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY THERAPY TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY DOSAGE FORM, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY DOSAGE FORM, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 13. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY AGE GROUP, 2024 VS 2032 (%)
  • FIGURE 15. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY AGE GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY INDICATION STAGE, 2024 VS 2032 (%)
  • FIGURE 17. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY INDICATION STAGE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AMERICAS CELIAC DISEASE DRUGS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. NORTH AMERICA CELIAC DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. LATIN AMERICA CELIAC DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA CELIAC DISEASE DRUGS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. EUROPE CELIAC DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. MIDDLE EAST CELIAC DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. AFRICA CELIAC DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. ASIA-PACIFIC CELIAC DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. ASEAN CELIAC DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. GCC CELIAC DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 30. EUROPEAN UNION CELIAC DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 31. BRICS CELIAC DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 32. G7 CELIAC DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 33. NATO CELIAC DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 34. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 35. CELIAC DISEASE DRUGS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 36. CELIAC DISEASE DRUGS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. CELIAC DISEASE DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY ENZYME THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY ENZYME THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY ENZYME THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY ENZYME THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY ENZYME THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY ENZYME THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY IMMUNOMODULATOR THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY IMMUNOMODULATOR THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY IMMUNOMODULATOR THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY IMMUNOMODULATOR THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY IMMUNOMODULATOR THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY IMMUNOMODULATOR THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY PROBIOTIC THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY PROBIOTIC THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY PROBIOTIC THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY PROBIOTIC THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY PROBIOTIC THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY PROBIOTIC THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY BIOLOGICAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY BIOLOGICAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY BIOLOGICAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY BIOLOGICAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY BIOLOGICAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY BIOLOGICAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY SMALL MOLECULE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY SMALL MOLECULE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY SMALL MOLECULE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY SMALL MOLECULE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY SMALL MOLECULE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY SMALL MOLECULE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY INJECTABLE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY INJECTABLE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY ORAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY ORAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY ORAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY PRIVATE HOSPITAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY PRIVATE HOSPITAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY PRIVATE HOSPITAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY PRIVATE HOSPITAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY PRIVATE HOSPITAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY PRIVATE HOSPITAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY PUBLIC HOSPITAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY PUBLIC HOSPITAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY PUBLIC HOSPITAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY PUBLIC HOSPITAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY PUBLIC HOSPITAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY PUBLIC HOSPITAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY ONLINE PHARMACIES, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY ONLINE PHARMACIES, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY OTC SERVICE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY OTC SERVICE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY OTC SERVICE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY OTC SERVICE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY OTC SERVICE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY OTC SERVICE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY PRESCRIPTION SERVICE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY PRESCRIPTION SERVICE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY PRESCRIPTION SERVICE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY PRESCRIPTION SERVICE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY PRESCRIPTION SERVICE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY PRESCRIPTION SERVICE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY CHAIN PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY CHAIN PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY CHAIN PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY CHAIN PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY CHAIN PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY CHAIN PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY INDEPENDENT PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY INDEPENDENT PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY INDEPENDENT PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY INDEPENDENT PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY INDEPENDENT PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY INDEPENDENT PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY INJECTABLE FORMULATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY INJECTABLE FORMULATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY INJECTABLE FORMULATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY INJECTABLE FORMULATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY INJECTABLE FORMULATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY INJECTABLE FORMULATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY ORAL CAPSULES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY ORAL CAPSULES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY ORAL CAPSULES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY ORAL CAPSULES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY ORAL CAPSULES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY ORAL CAPSULES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY ORAL TABLETS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY ORAL TABLETS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY ORAL TABLETS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY ORAL TABLETS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY ORAL TABLETS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY ORAL TABLETS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY POWDER FORM, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY POWDER FORM, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY POWDER FORM, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY POWDER FORM, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY POWDER FORM, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY POWDER FORM, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY HOMECARE SETTINGS, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY HOMECARE SETTINGS, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY HOMECARE SETTINGS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY HOMECARE SETTINGS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY HOMECARE SETTINGS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY HOMECARE SETTINGS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY HOMECARE SETTINGS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY HOMECARE SETTINGS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY NURSE ASSISTED ADMINISTRATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY NURSE ASSISTED ADMINISTRATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY NURSE ASSISTED ADMINISTRATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY NURSE ASSISTED ADMINISTRATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY NURSE ASSISTED ADMINISTRATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY NURSE ASSISTED ADMINISTRATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY SELF ADMINISTRATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY SELF ADMINISTRATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY SELF ADMINISTRATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY SELF ADMINISTRATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY SELF ADMINISTRATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY SELF ADMINISTRATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY PRIVATE HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY PRIVATE HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY PRIVATE HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY PRIVATE HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY PUBLIC HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY PUBLIC HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY PUBLIC HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY PUBLIC HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY SPECIALTY CLINICS, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY GASTROENTEROLOGY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY GASTROENTEROLOGY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY GASTROENTEROLOGY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY GASTROENTEROLOGY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY GASTROENTEROLOGY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY GASTROENTEROLOGY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY GENERAL CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY GENERAL CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY GENERAL CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY GENERAL CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY GENERAL CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY GENERAL CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY ADULTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY ADULTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY ADULTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY ADULTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY ADULTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY ADULTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY PEDIATRICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY PEDIATRICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY PEDIATRICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY PEDIATRICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY PEDIATRICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY PEDIATRICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY INDICATION STAGE, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY INDICATION STAGE, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY ACUTE MANAGEMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY ACUTE MANAGEMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY ACUTE MANAGEMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY ACUTE MANAGEMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY ACUTE MANAGEMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY ACUTE MANAGEMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY MAINTENANCE THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY MAINTENANCE THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY MAINTENANCE THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY MAINTENANCE THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY MAINTENANCE THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY MAINTENANCE THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 233. AMERICAS CELIAC DISEASE DRUGS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 234. AMERICAS CELIAC DISEASE DRUGS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 235. AMERICAS CELIAC DISEASE DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 236. AMERICAS CELIAC DISEASE DRUGS MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 237. AMERICAS CELIAC DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 238. AMERICAS CELIAC DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 239. AMERICAS CELIAC DISEASE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 240. AMERICAS CELIAC DISEASE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 241. AMERICAS CELIAC DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 242. AMERICAS CELIAC DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 243. AMERICAS CELIAC DISEASE DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2024 (USD MILLION)
  • TABLE 244. AMERICAS CELIAC DISEASE DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2025-2032 (USD MILLION)
  • TABLE 245. AMERICAS CELIAC DISEASE DRUGS MARKET SIZE, BY ONLINE PHARMACIES, 2018-2024 (USD MILLION)
  • TABLE 246. AMERICAS CELIAC DISEASE DRUGS MARKET SIZE, BY ONLINE PHARMACIES, 2025-2032 (USD MILLION)
  • TABLE 247. AMERICAS CELIAC DISEASE DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2024 (USD MILLION)
  • TABLE 248. AMERICAS CELIAC DISEASE DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2025-2032 (USD MILLION)
  • TABLE 249. AMERICAS CELIAC DISEASE DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 250. AMERICAS CELIAC DISEASE DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 251. AMERICAS CELIAC DISEASE DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 252. AMERICAS CELIAC DISEASE DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 253. AMERICAS CELIAC DISEASE DRUGS MARKET SIZE, BY HOMECARE SETTINGS, 2018-2024 (USD MILLION)
  • TABLE 254. AMERICAS CELIAC DISEASE DRUGS MARKET SIZE, BY HOMECARE SETTINGS, 2025-2032 (USD MILLION)
  • TABLE 255. AMERICAS CELIAC DISEASE DRUGS MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 256. AMERICAS CELIAC DISEASE DRUGS MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 257. AMERICAS CELIAC DISEASE DRUGS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 258. AMERICAS CELIAC DISEASE DRUGS MARKET SIZE, BY SPECIALTY CLINICS, 2025-2032 (USD MILLION)
  • TABLE 259. AMERICAS CELIAC DISEASE DRUGS MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 260. AMERICAS CELIAC DISEASE DRUGS MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 261. AMERICAS CELIAC DISEASE DRUGS MARKET SIZE, BY INDICATION STAGE, 2018-2024 (USD MILLION)
  • TABLE 262. AMERICAS CELIAC DISEASE DRUGS MARKET SIZE, BY INDICATION STAGE, 2025-2032 (USD MILLION)
  • TABLE 263. NORTH AMERICA CELIAC DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 264. NORTH AMERICA CELIAC DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 265. NORTH AMERICA CELIAC DISEASE DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 266. NORTH AMERICA CELIAC DISEASE DRUGS MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 267. NORTH AMERICA CELIAC DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 268. NORTH AMERICA CELIAC DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 269. NORTH AMERICA CELIAC DISEASE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 270. NORTH AMERICA CELIAC DISEASE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 271. NORTH AMERICA CELIAC DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 272. NORTH AMERICA CELIAC DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 273. NORTH AMERICA CELIAC DISEASE DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2024 (USD MILLION)
  • TABLE 274. NORTH AMERICA CELIAC DISEASE DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2025-2032 (USD MILLION)
  • TABLE 275. NORTH AMERICA CELIAC DISEASE DRUGS MARKET SIZE, BY ONLINE PHARMACIES, 2018-2024 (USD MILLION)
  • TABLE 276. NORTH AMERICA CELIAC DISEASE DRUGS MARKET SIZE, BY ONLINE PHARMACIES, 2025-2032 (USD MILLION)
  • TABLE 277. NORTH AMERICA CELIAC DISEASE DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2024 (USD MILLION)
  • TABLE 278. NORTH AMERICA CELIAC DISEASE DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2025-2032 (USD MILLION)
  • TABLE 279. NORTH AMERICA CELIAC DISEASE DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 280. NORTH AMERICA CELIAC DISEASE DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 281. NORTH AMERICA CELIAC DISEASE DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 282. NORTH AMERICA CELIAC DISEASE DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 283. NORTH AMERICA CELIAC DISEASE DRUGS MARKET SIZE, BY HOMECARE SETTINGS, 2018-2024 (USD MILLION)
  • TABLE 284. NORTH AMERICA CELIAC DISEASE DRUGS MARKET SIZE, BY HOMECARE SETTINGS, 2025-2032 (USD MILLION)
  • TABLE 285. NORTH AMERICA CELIAC DISEASE DRUGS MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 286. NORTH AMERICA CELIAC DISEASE DRUGS MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 287. NORTH AMERICA CELIAC DISEASE DRUGS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 288. NORTH AMERICA CELIAC DISEASE DRUGS MARKET SIZE, BY SPECIALTY CLINICS, 2025-2032 (USD MILLION)
  • TABLE 289. NORTH AMERICA CELIAC DISEASE DRUGS MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 290. NORTH AMERICA CELIAC DISEASE DRUGS MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 291. NORTH AMERICA CELIAC DISEASE DRUGS MARKET SIZE, BY INDICATION STAGE, 2018-2024 (USD MILLION)
  • TABLE 292. NORTH AMERICA CELIAC DISEASE DRUGS MARKET SIZE, BY INDICATION STAGE, 2025-2032 (USD MILLION)
  • TABLE 293. LATIN AMERICA CELIAC DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 294. LATIN AMERICA CELIAC DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 295. LATIN AMERICA CELIAC DISEASE DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 296. LATIN AMERICA CELIAC DISEASE DRUGS MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 297. LATIN AMERICA CELIAC DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 298. LATIN AMERICA CELIAC DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 299. LATIN AMERICA CELIAC DISEASE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 300. LATIN AMERICA CELIAC DISEASE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 301. LATIN AMERICA CELIAC DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 302. LATIN AMERICA CELIAC DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 303. LATIN AMERICA CELIAC DISEASE DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2024 (USD MILLION)
  • TABLE 304. LATIN AMERICA CELIAC DISEASE DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2025-2032 (USD MILLION)
  • TABLE 305. LATIN AMERICA CELIAC DISEASE DRUGS MARKET SIZE, BY ONLINE PHARMACIES, 2018-2024 (USD MILLION)
  • TABLE 306. LATIN AMERICA CELIAC DISEASE DRUGS MARKET SIZE, BY ONLINE PHARMACIES, 2025-2032 (USD MILLION)
  • TABLE 307. LATIN AMERICA CELIAC DISEASE DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2024 (USD MILLION)
  • TABLE 308. LATIN AMERICA CELIAC DISEASE DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2025-2032 (USD MILLION)
  • TABLE 309. LATIN AMERICA CELIAC DISEASE DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 310. LATIN AMERICA CELIAC DISEASE DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 311. LATIN AMERICA CELIAC DISEASE DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 312. LATIN AMERICA CELIAC DISEASE DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 313. LATIN AMERICA CELIAC DISEASE DRUGS MARKET SIZE, BY HOMECARE SETTINGS, 2018-2024 (USD MILLION)
  • TABLE 314. LATIN AMERICA CELIAC DISEASE DRUGS MARKET SIZE, BY HOMECARE SETTINGS, 2025-2032 (USD MILLION)
  • TABLE 315. LATIN AMERICA CELIAC DISEASE DRUGS MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 316. LATIN AMERICA CELIAC DISEASE DRUGS MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 317. LATIN AMER